Equities Analysts Issue Forecasts for ARWR FY2025 Earnings

Key Points

• Leerink Partners has reduced its FY2025 earnings per share (EPS) estimate for Arrowhead Pharmaceuticals from $1.35 to $1.15, contrasting with the current consensus estimate of ($2.42) EPS.
• Various analysts have issued mixed ratings for Arrowhead Pharmaceuticals, with three giving a hold rating, six a buy rating, and one a strong buy rating, reflecting a consensus rating of Moderate Buy.
• The company's stock has a market cap of $2.27 billion and has shown significant volatility, with a 1-year low of $9.57 and a high of $27.34.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 5th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings of $1.15 per share for the year, down from their previous estimate of $1.35. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at $0.86 EPS and FY2027 earnings at ($2.30) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter last year, the firm earned ($1.38) EPS.

ARWR has been the subject of several other reports. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Royal Bank Of Canada decreased their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research note on Friday. Wall Street Zen cut Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Finally, Citigroup decreased their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $43.14.

Arrowhead Pharmaceuticals Trading Up 2.2%

Shares of NASDAQ ARWR traded up $0.36 during midday trading on Wednesday, reaching $16.42. 2,806,298 shares of the stock were exchanged, compared to its average volume of 2,030,270. The stock has a market capitalization of $2.27 billion, a P/E ratio of -12.83, a PEG ratio of 23.18 and a beta of 0.94. The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.15 and a current ratio of 5.15. The company has a 50 day simple moving average of $16.48 and a 200 day simple moving average of $15.99. Arrowhead Pharmaceuticals has a twelve month low of $9.57 and a twelve month high of $27.34.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Resona Asset Management Co. Ltd. purchased a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $420,000. Wells Fargo & Company MN lifted its holdings in Arrowhead Pharmaceuticals by 43.1% during the 4th quarter. Wells Fargo & Company MN now owns 62,886 shares of the biotechnology company's stock worth $1,182,000 after buying an additional 18,933 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $360,000. Bank of Montreal Can boosted its position in Arrowhead Pharmaceuticals by 13.3% in the 4th quarter. Bank of Montreal Can now owns 15,018 shares of the biotechnology company's stock valued at $282,000 after buying an additional 1,759 shares during the period. Finally, ADAR1 Capital Management LLC grew its stake in shares of Arrowhead Pharmaceuticals by 10.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company's stock worth $243,000 after acquiring an additional 1,195 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.